Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A new examination of Sustiva- and Viramune-based triple-drug regimens has shown that it isn't the choice between the two nonnucleoside analogs that predicts long-term viral control among treatment-naive HIVers but rather the accompanying nucleosides. The review, published in the April 6 issue of the Journal of Acquired Immune Deficiency Syndromes, shows that both Sustiva and Viramune are most successful when paired with two newer nukes than with such older combinations as Zerit plus Epivir or Videx plus Viread.
From our Sponsors
Most Popular
Plus: Featured Video